Rigel Pharmaceuticals, Inc. RIGL
Set alert
At close · Oct 30
After hours · Oct 30, 6:58 PM ET
- YTD
- +19.80%
- 1 year
- +62.27%
- Open
- 51.80
- Prev close
- 51.45
- Mkt cap
- 949.34M
- Vol
- 174.41K
- Avg vol
- 260.05K
- EPS
- 16.88
- P/E
- 3.04
- Div yield
- 0.00%
More statistics
- Low
- 50.67
- High
- 52.61
- Forward P/E
- 19.49
- Beta
- 0.95
- Short ratio
- 1.69
- Inst. own
- 68.01%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.01
- 200-d avg
- 13.77
- 1y target
- 31.33
3M chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 1 month ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 302.10M
- Enterprise value
- 340.14M
- Trailing P/E
- 63.52
- Forward P/E
- 19.49
- PEG ratio
- 0.00
- Price / sales
- 1.92
- Price / book
- 0.00
- EPS (TTM)
- 0.27
- Beta
- 0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 2.47%
- Revenue (TTM)
- 157.37M
- Revenue growth
- 96.60%
- Free cash flow
- 13.14M
- Total cash
- 61.11M
- Total debt
- 100.21M
- Return on equity
- 0.00%
- Shares outstanding
- 17.61M
- Short % of float
- 2.73%
- 50-day average
- 20.01
- 200-day average
- 13.77
Analyst view
Consensus: buy
- Target (low)
- 14.00
- Target (mean)
- 31.33
- Target (high)
- 57.00
- Strong buy1
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.33401.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.01 | 0.70 | +0.69 | +6,900.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.37 | -0.06 | +0.31 | +83.78% |
| May 7, 2024 | Mar 1, 2024 | -0.30 | -0.50 | -0.20 | -66.67% |
| Mar 5, 2024 | Dec 1, 2023 | -0.30 | 0.00 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -0.70 | -0.30 | +0.40 | +57.14% |
| Aug 1, 2023 | Jun 1, 2023 | -0.80 | -0.40 | +0.40 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Cantor Fitzgerald | main | Neutral | Neutral |
| Dec 10, 2024 | B. Riley Securities | main | Neutral | Neutral |
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 6, 2024 | B. Riley Securities | main | Neutral | Neutral |
| Nov 14, 2024 | Piper Sandler | main | Neutral | Neutral |
| Nov 12, 2024 | Citigroup | main | Buy | Buy |
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rigel.com
News
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
- HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target
- Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49
- HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85
- Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $275.000M-$290.000M to $285.000M-$295.000M vs $308.461M Est
- Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate
- Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement
- HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Your note
Sign in to keep a note on RIGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI-JACKSON KAMIL | Director | Stock Award(Grant) | May 23, 2024 | 68,750 |
| FUREY RAYMOND J | General Counsel | Stock Award(Grant) | Jan 22, 2024 | 214,000 |
| HANNAH ALISON L. | Director | Stock Award(Grant) | May 23, 2024 | 81,250 |
| KOTZIN BRIAN L | Director | Stock Award(Grant) | May 23, 2024 | 100,000 |
| LAPOINTE ANTHONY GREGG | Director | Stock Award(Grant) | May 23, 2024 | 100,000 |
| MOOS WALTER H | Director | Stock Award(Grant) | May 23, 2024 | 102,222 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.86% | 1,561,443 | 26.78M | Sep 29, 2024 |
| Armistice Capital, LLC | 8.72% | 1,536,000 | 26.34M | Sep 29, 2024 |
| Morgan Stanley | 8.31% | 1,463,499 | 25.10M | Sep 29, 2024 |
| Invesco Ltd. | 5.97% | 1,051,355 | 18.03M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 985,291 | 16.90M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 5.31% | 934,788 | 16.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 5.92% | 1,042,771 | 17.88M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.12% | 548,780 | 9.41M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.63% | 462,770 | 7.94M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.38% | 242,737 | 4.16M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.01% | 177,303 | 3.04M | Aug 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.91% | 160,000 | 2.74M | Sep 29, 2024 |